Are there generic versions of Adagrasib?

As far as we know, adagrasib (Adagrasib) has not yet been produced and launched as a generic drug. The U.S. Food and Drug Administration (FDA) approved the launch of the original drug of adagrasil in February 2022, with the trade name KRAZATI, for the treatment of patients who have previously been treated for KRAS 12c-positive non-small cell lung cancer (NSCLC), and accelerated approval in December 2022 for the treatment of KRAS Patients with 12c-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy.

Adagrasiibisan orally effective, irreversible small molecule inhibitor of KRAS G12C mutant isoform, developed by Mirati Therapeutics. It was approved under accelerated approval based on objective response rate and duration of response. Its continued approval for this indication may depend on the verification and description of clinical benefit in confirmatory trials. Adagrasibtargets KRAS 12c, which is one of the most common KRAS mutations, located at cysteine u200bu200b12 residues, and inhibits KRAS-dependent signaling. In a Phase I/IB clinical study that included patients with KRAS 12c-mutated advanced solid tumors, adagrasib was shown to be effective without new safety signals in patients with KRAS G12C-mutated non-small cell lung cancer.

Since Adgrasib has not yet been marketed in the country, it has not been included in medical insurance. There is an American version of the original drug Adagrasibu listed overseas. SpecificationsThe price per box of 120mg*180 tablets is around RMB 180,000 (the price may fluctuate due to the exchange rate), which is expensive. For more drug information and specific prices, please consult Yaodei Medical Consultant.